Salix Pharmaceuticals Reports 3Q2012 Results Management Maintains 2012 Revenue Guidance of $735 Million And Increases Guidance for Adjusted Net Income to $200 Million or $3.13, Per Share, Fully Diluted 27% Increase in Year-over-Year 3Q Product Revenue 20% Increase in Year-over-Year 3Q XIFAXAN^® Prescriptions on a Milligram Basis 24% Increase in Year-over-Year 3Q APRISO^® Prescriptions 89% Increase in Year-over-Year 3Q RELISTOR^® Prescriptions Business Wire RALEIGH, N.C. -- November 07, 2012 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2012 and other business updates. Total product revenue was $185.1 million for the third quarter of 2012, a 27% increase compared to $146.2 million for the third quarter of 2011. Total product revenue for the first nine months of 2012 was $537.3 million, a 39% increase compared to $385.3 million for the first nine months of 2011. XIFAXAN^® revenue for the third quarter of 2012 was $137.9 million, a 43% increase compared to $96.7 million for the third quarter of 2011. XIFAXAN revenue for the first nine months of 2012 was $367.5 million, a 39% increase compared to $264.4 million for the first nine months of 2011. APRISO^® revenue for the third quarter of 2012 was $19.7 million, a 31% increase compared to $15.0 million for the third quarter of 2011. The combined revenue contribution of our most recently-introduced products - RELISTOR^®, SOLESTA^® and DEFLUX^®- totaled $12.1 million for the third quarter of 2012. Total cost of products sold was $26.5 million for the third quarter of 2012 and $93.9 million for the first nine months of 2012, compared to $24.1 million for the third quarter of 2011 and $67.9 million for the first nine months of 2011. Gross margin on total product revenue was 85.7% for the third quarter of 2012 compared to 83.5% for the third quarter of 2011, and 82.5% for the first nine months of 2012 compared to 82.4% for the first nine months of 2011. Research and development expenses were $32.8 million for the third quarter of 2012 and $86.7 million for the first nine months of 2012, compared to $24.8 million and $85.3 million, respectively, for the prior year periods. The increase in research and development expenses for 2012 compared to 2011 is due primarily to increased expenses related to our Phase 3 retreatment study of rifaximin for irritable bowel syndrome with diarrhea. Selling, general and administrative expenses were $61.5 million for the third quarter of 2012 compared to $41.4 million for the prior year period and $187.3 million for the first nine months of 2012 compared to $132.8 million for the prior year period. The increase in selling, general and administration expenses for 2012 compared to 2011 is due primarily to increased personnel costs related to our sales force expansion in 2012 and increased marketing expenses related to SOLESTA and XIFAXAN550 for hepatic encephalopathy. The Company reported GAAP net income of $16.5 million, or $0.26 per share, fully diluted, for the third quarter of 2012 and $46.6 million, or $0.73 per share, fully diluted, for the nine-month period ended September 30, 2012. Net income on a non-GAAP basis, excluding the loss on extinguishment of debt and non-cash adjustments related to the repurchase of a portion of our 2028 Notes in March 2012, the intangible asset impairment charge and change in acquisition-related contingent consideration that occurred in September 2012, the difference between income taxes paid and income taxes expensed, and non-cash depreciation, amortization, stock-based compensation and convertible debt interest expense, was $59.7 million, or $0.95 per share, fully diluted, for the three-month period ended September 30, 2012 and $154.5 million or $2.43 per share, fully diluted for the nine-month period ended September 30, 2012. We believe these non-GAAP measures might provide investors additional relevant information, in part for purposes of historical comparison. In addition, we use these non-GAAP measures to analyze our performance in more detail and with better historical comparability; however, you should be aware that non-GAAP measures are not superior to, nor a substitute for, the comparable GAAP measures. We have provided a reconciliation of these measures to the most closely related GAAP measures in the accompanying financial tables. Cash and cash equivalents were $775.9 million as of September 30, 2012. Adam Derbyshire, Executive Vice President and Chief Financial Officer, stated, “XIFAXAN 550 mg continued to perform well during the third quarter of 2012. During the quarter our XIFAXAN prescription business, comprised of XIFAXAN 200 mg tablets and XIFAXAN 550 mg tablets, demonstrated impressive growth, on a milligram basis, of 20% compared to the third quarter of 2011. APRISO also demonstrated strong prescription year-over-year growth of 24% for the third quarter of 2012 compared to the third quarter of 2011. RELISTOR prescriptions increased 89% year-over-year for the third quarter of 2012 compared to the third quarter of 2011. “We continue to believe total Company product revenue for 2012 will be approximately $735 million, representing 36% growth over 2011 revenue. We now believe we will be able to generate adjusted net income of approximately $200 million, or $3.13 per share, fully diluted on the non-GAAP basis described above for the full year ending December 31, 2012. “The current annualized run rates, based on dollarizing the August 2012 prescription data for XIFAXAN, MOVIPREP/OSMOPREP, APRISO, RELISTOR (U.S.) and our ’other products’, are approximately $495 million, $108 million, $87 million, $32 million, and $48 million, respectively. In line with the full year 2012 guidance provided above, for the fourth quarter of 2012 we anticipate total Company product revenue should be approximately $198 million and adjusted net income should be approximately $46 million, or $0.72 per share, fully diluted, on the non-GAAP basis described above.” Carolyn Logan, President and Chief Executive Officer, stated, “Our third quarter growth was driven primarily by XIFAXAN 550, APRISO and RELISTOR. XIFAXAN continues to grow sequentially, with prescriptions, on a milligram basis, increasing 5% for the third quarter of 2012 compared to the second quarter of 2012. APRISO also continued to exceed the Company’s expectations during the quarter. APRISO prescriptions increased 4% during the third quarter of 2012 compared to the second quarter of 2012. RELISTOR prescriptions increased 18% during the third quarter of 2012 compared to the second quarter of 2012. “During the third quarter our sales force continued launching SOLESTA^® - our first-in-class, biocompatible tissue bulking agent for the treatment of fecal incontinence, or FI. Fecal incontinence is estimated to affect approximately 15% of people in the United States over the age of 50 and is the leading reason for admission to assisted living facilities in the United States. Physicians and patients have shown significant interest in the use of SOLESTA as an alternative to more invasive treatment options in the treatment of FI. In early November the Centers for Medicare and Medicaid Services (CMS) assigned SOLESTA a unique HCPCS code of “L8605” for reimbursement purposes. This new code will facilitate separate reimbursement for SOLESTA across multiple settings of care. SOLESTA will be billed under the new code L8605 (Injectable Bulking Agent, Anal Canal) effective January 1, 2013. “On July 27, 2012 the Company received from the FDA a Complete Response Letter (CRL) requesting additional clinical data for our supplemental New Drug Application (sNDA) for RELISTOR (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. On October 5, 2012 Salix conducted an End-of-Review meeting with the FDA’s Division of Gastroenterology and Inborn Errors Products to better understand the contents of the letter. The Division has expressed a concern that there may be a risk associated with the chronic use of mu-opioid antagonists in patients that are taking opioids for chronic pain. In order to understand this potential risk, the Division has communicated that a very large, well-controlled, chronic administration trial will have to be conducted to assess the safety of any mu-opioid antagonist prior to market approval for the treatment of patients with OIC who are taking opioids for chronic, non-cancer pain. Salix has held discussions with the Division and has expressed the view that the post-marketing, clinical and preclinical data currently available for RELISTOR adequately demonstrate an appropriate and expected safety profile sufficient to permit the approval of the current sNDA. “The Company plans to continue to work with the FDA to generate a reasonable path forward that can be agreed upon by both parties for the further development and regulatory review of RELISTOR. While it is not possible to definitively determine the duration of our discussion with the FDA regarding this matter, at this time we anticipate a path forward could be reached with the FDA during 2013. Opioid induced constipation is a debilitating and unmet medical need that occurs as a consequence of opioid use in some patients that are taking opioids for chronic pain. Currently, there are no FDA-approved therapies for OIC in chronic, non-cancer pain. Before changing our plans for development of RELISTOR, we intend to make every effort to gain approval for the expanded use of RELISTOR to extend the benefit RELISTOR has provided to relieving OIC in advanced illness patients since 2008 to meet the unmet medical need of OIC in patients with chronic, non-cancer pain. Based on the information discussed above, we reassessed the value of the indefinite lived intangible asset related to the chronic, non-cancer pain indication and recorded a non-cash charge to earnings of $41.6 million in the three-month period ended September 30, 2012. We also reassessed the fair value of the contingent consideration related to Relistor and recorded a $33.0 million decrease in the contingent consideration that resulted in a corresponding increase to earnings in the three-month period ended September 30, 2012. “In respect of the currently-approved subcutaneous formulation of RELISTOR for OIC in patients with advanced illness who are receiving palliative care, physician feedback indicates a significant need in the marketplace for a treatment that targets the underlying cause of OIC without impacting opioid–mediated analgesic effects on the central nervous system. RELISTOR does this by displacing opioid binding in tissues in the gastrointestinal tract. Since we introduced RELISTOR in April 2011, an increasing number of physicians have begun to treat their patients with advanced illness who are receiving palliative care with RELISTOR as a solution to OIC when response to laxative treatment has not been sufficient. In early November the Centers for Medicare and Medicaid Services (CMS) assigned RELISTOR a unique Healthcare Common Procedure Coding System, or HCPCS code, of “J2212” for reimbursement purposes. We initially estimated peak year sales of RELISTOR for advanced illness could reach $50 million. Based on RELISTOR’s performance over the past 18 months we are increasing our estimate of peak year sales to approximately $100 million for this indication. “We continue to anticipate an action by the FDA by the end of the first quarter of 2013 on our NDA for Crofelemer 125 mg tablets for the proposed indication of the control and symptomatic relief of diarrhea in patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy. Both the FDA and Salix are continuing to work collaboratively to progress this important product through its full review. To date, this collaboration has resulted in substantial progress in handling topics important to crofelemer as well as to future botanical products in general. The primary focus of our collaboration is the production and control of the crofelemer active pharmaceutical ingredient in order to ensure compliance with the manufacturing and product quality requirements of the Federal Food, Drug & Cosmetic Act. Both Salix and the FDA are committed to a robust level of cooperation and data exchange with the goal of providing crofelemer to patients suffering from the very important unmet need of the indication for which we are seeking approval. Our efforts to date have advanced both the chemical and the regulatory science methods available to ensure the quality and clinical usefulness of crofelemer and, potentially, other products that are of botanical origin. “On February 21, 2012 the Company initiated TARGET 3 - a Phase 3 study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days in subjects with irritable bowel syndrome with diarrhea (IBS-D) who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. During the third quarter we continued to enroll a number of subjects sufficient to randomize approximately 800 subjects (400 subjects per treatment group) into the double blind retreatment phase of the study. We initiated patient enrollment in TARGET 3 during the first half of 2012 and currently anticipate securing a FDA decision regarding approvability during the first half of 2014. We continue to strengthen our intellectual property relating to rifaximin for the treatment of IBS-D. A method of treatment patent regarding XIFAXAN550 for the treatment of IBS-D should issue November 13, 2012 and should provide protection until 2029. “In August Salix entered into an exclusive agreement with Alfa Wassermann S.p.A. by which we licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn’s disease. The EIR formulation of rifaximin has been designed to provide an efficient delivery of rifaximin by releasing the active drug following passage through the stomach in order to provide a homogeneous distribution of rifaximin in the intestinal tract. This EIR formulation of rifaximin will be studied for its potential to target difficult to treat diseases of the intestinal tract such as Crohn’s disease. We intend to initiate two Phase 3 trials during the first half of 2013 with the goal of securing FDA approval to market EIR rifaximin for the treatment of Crohn’s disease. “We received the rights to EIR formulation rifaximin products as part of a restructuring of long-standing arrangements between Alfa Wassermann and Salix for the development and commercialization of rifaximin products in the United States and Canada for gastrointestinal and respiratory indications. The restructuring does not affect arrangements for the rifaximin products currently approved in the Salix territory, nor for any product for treatment of irritable bowel syndrome that might be approved in the future. Under the new arrangements, Salix has provided Alfa Wassermann with rights to obtain a license to develop and commercialize, outside the United States and Canada for gastrointestinal and respiratory indications, formulations of rifaximin currently being developed by Salix and other new formulations of rifaximin that Salix may develop in the future. “During the third quarter of 2012 the Company also continued to make progress in the development of budesonide foam, a new formulation of rifaximin and LUMACAN™. We anticipate completing patient enrollment in our two budesonide foam Phase 3 trials by the end of 2012. Currently we are targeting submission of the NDA for budesonide foam for the treatment of moderate ulcerative proctitis or proctosigmoiditis during the third quarter of 2013. Regarding our next generation formulation of rifaximin, our pharmacokinetic study to assist in the characterization of three prototype tablet formulations progressed during the third quarter of 2012, and currently we intend to move forward with the initiation of a clinical trial in the first half of 2013. Work continued to progress on the development of LUMACAN oral formulation prototypes. During the third quarter we initiated an exploratory study designed to evaluate fluorescence kinetics of LUMACAN following enema administration for precancerous and cancerous lesions, in respect of the quality, onset and offset of fluorescence following administration of the enema. If the enema administration is successful, we intend to proceed to orally administered test formulations. We believe that LUMACAN, if approved, has the potential to significantly improve earlier detection and diagnosis of colon cancer. “During the third quarter we received a paragraph IV notification from Lupin Limited stating that Lupin had filed an ANDA application to seek approval to market a generic version of APRISO. The notification letter asserted non-infringement and invalidity of the Company’s Orange Book-listed U.S. Patent No.6,551,620. On September 7, 2012 Salix and Dr. Falk Pharma filed a patent infringement complaint against Lupin. The filing of this suit imposes an automatic 30-month stay of approval of Lupin’s ANDA. We have full confidence in and continue to evaluate our intellectual property protecting APRISO, and we intend to vigorously enforce our intellectual property rights. “Salix is built on a tremendous history of success – including the approval of eight New Drug Applications, the acquisition/licensing of 16 products and the establishment of a top-ranked specialty sales force since 2000. Our core business remains strong and continues to grow. Our portfolio of marketed products is complemented by our impressive pipeline of product candidates in development that should drive additional revenue growth over the long term as they are commercialized. Additionally, the Company continues to actively pursue additional product opportunities to expand and broaden our product portfolio. We are extremely pleased with the success we have achieved to date, and we believe the Company is well-positioned to continue to succeed in our mission of being the leading specialty pharmaceutical company licensing, developing and marketing innovative products to healthcare professionals to prevent or treat gastrointestinal disorders.” The Company will host a conference call at 5:00 p.m. ET, on Wednesday, November 7, 2012. Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at www.salix.com. A replay of the web cast will be available at the same location. The telephone numbers to access the live conference call are (877) 756-4253 (U.S. and Canada) or (706) 902-2163 (international.) The telephone numbers to access the replay of the call are (855) 859-2056 or (800) 585-8367 (U.S. and Canada) or (404) 537-3406 (international). The access code for the replay is 95498100. About Salix Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team. Salix markets XIFAXAN^® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP^® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP^® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO^® (mesalamine) extended-release capsules 0.375 g, METOZOLV^® ODT (metoclopramide HCl), RELISTOR^® (methylnaltrexone bromide) Subcutaneous Injection, SOLESTA^®, DEFLUX^®, PEPCID^® (famotidine) for Oral Suspension, Oral Suspension DIURIL^® (Chlorothiazide), AZASAN^® (Azathioprine) Tablets, USP, 75/100 mg, ANUSOL-HC^® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC^® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT^® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT^® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Crofelemer, budesonide foam, RELISTOR^® , LUMACAN^™ and rifaximin for additional indications are under development. For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP, AZASAN and METOZOLV, please visit www.salix.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at 919 862-1000. Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”. For more information, please visit our Website at www.salix.com or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our SEC filings. Please Note: The materials provided herein contain projections and other forward–looking statements regarding future events. Such statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; generic and other competition in an increasingly global industry; litigation and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties in an increasingly global industry; the cost, timing and results of clinical trials and other development activities involving pharmaceutical products; post-marketing approval regulation; market acceptance for approved products; revenue recognition and other critical accounting policies; and the need to acquire new products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission. Salix Pharmaceuticals, Ltd. Condensed Consolidated Statements of Operations (In thousands, except per share Three Months Ended Nine Months Ended data) September 30, September 30, September September 30, 30, 2012 2011 2012 2011 (unaudited) (unaudited) (unaudited) (unaudited) Revenues: Net product revenues $ 185,132 $ 146,247 $ 537,271 $ 385,306 Costs and Expenses: Cost of products sold 26,471 24,056 93,918 67,884 Amortization of product rights 11,345 2,890 34,034 8,017 and intangible assets Research and development 32,819 24,814 86,677 85,294 Selling, general and 61,543 41,439 187,266 132,786 administrative Intangible asset impairment 41,600 - 41,600 - charge Change in acquisition-related (31,398 ) - (31,398 ) - contingent consideration Total costs and expenses 142,380 93,199 412,097 293,981 Income from operations 42,752 53,048 125,174 91,325 Loss on extinguishment of debt - - (14,369 ) - Interest expense (15,692 ) (8,080 ) (39,591 ) (23,932 ) Interest and other income 279 509 10,409 2,082 Income before income tax 27,339 45,477 81,623 69,475 Income tax expense 10,803 11,198 35,000 15,671 Net Income $ 16,536 $ 34,279 $ 46,623 $ 53,804 Income per share, basic $ 0.28 $ 0.58 $ 0.79 $ 0.92 Income per share, diluted $ 0.26 $ 0.55 $ 0.73 $ 0.89 Shares used in computing net 58,755 59,076 58,671 58,573 income per share, basic Shares used in computing net 62,983 65,160 63,689 65,405 income per share, diluted Reconciliation of GAAP Amounts to Non-GAAP Amounts: (In thousands, except per share data) We are disclosing our non-GAAP Condensed Consolidated Statements of Operations, as adjusted, to eliminate the impact of the $10.0 million Lupin payment that occured in February 2011, the loss on extinguishment of debt and non-cash adjustments related to the repurchase of a portion of our 2028 Notes in March 2012, the intangible asset impairment charge and change in acquisition-related contingent consideration that occurred in September 2012, the difference between income taxes paid and income taxes expensed, and non-cash depreciation, amortization, stock-based compensation and convertible debt interest expenses that occured in the three-month and nine-month periods ended September 30, 2012 and 2011, respectively. We believe these non-GAAP measures might provide investors additional relevant information, in part for purposes of historical comparison. In addition, we use these non-GAAP measures to analyze our performance in more detail and with better historical comparability; however, you should be aware that non-GAAP measures are not superior to nor a substitute for the comparable GAAP measures. A reconciliation of our non-GAAP measures to the comparable GAAP measures follows. Three Months Ended Three Months Ended September September 30, September 30, September September September 30, 30, 30, 30, 2012 - 2012- 2011 - 2011 - 2012 Non-GAAP Non-GAAP 2011 Non-GAAP Non-GAAP Adjustments Adjustments as adjusted as adjusted (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Revenues: Net product $ 185,132 $ - $ 185,132 $ 146,247 $ - $ 146,247 revenues Costs and Expenses: Cost of products 26,471 - 26,471 24,056 - 24,056 sold Amortization of product rights and 11,345 (11,345 ) - 2,890 (2,890 ) - intangible assets Research and 32,819 (1,455 ) 31,364 24,814 (2,531 ) 22,283 development Selling, general 61,543 (5,824 ) 55,719 41,439 (4,124 ) 37,315 and administrative Intangible asset 41,600 (41,600 ) - - - - impairment charge Change in acquisition-related (31,398 ) 31,398 - - - - contingent consideration Total costs and 142,380 (28,826 ) 113,554 93,199 (9,545 ) 83,654 expenses Income from 42,752 28,826 71,578 53,048 9,545 62,593 operations Loss on extinguishment of - - - - - - debt Interest expense (15,692 ) 10,380 (5,312 ) (8,080 ) 4,882 (3,198 ) Interest and other 279 - 279 509 - 509 income Income before 27,339 39,206 66,545 45,477 14,427 59,904 income tax Income tax expense 10,803 (3,969 ) 6,834 11,198 - 11,198 Net Income, as $ 16,536 $ 43,175 $ 59,711 $ 34,279 $ 14,427 $ 48,706 adjusted Income per share, $ 0.28 $ 0.73 $ 1.02 $ 0.58 $ 0.24 $ 0.82 basic Income per share, $ 0.26 $ 0.69 $ 0.95 $ 0.55 $ 0.22 $ 0.77 diluted Shares used in computing net income 58,755 58,755 58,755 59,076 59,076 59,076 per share, basic Shares used in computing net income 62,983 62,983 62,983 65,160 65,160 65,160 per share, diluted Nine Months Ended Nine Months Ended September September 30, September 30, September September September 30, 30, 30, 30, 2012- 2012 - Non-GAAP 2011 - 2011 - 2012 Non-GAAP 2011 Non-GAAP Non-GAAP Adjustments as adjusted Adjustments as adjusted (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Revenues: Net product $ 537,271 $ - $ 537,271 $ 385,306 $ - $ 385,306 revenues Costs and Expenses: Cost of products 93,918 - 93,918 67,884 - 67,884 sold Amortization of product rights and 34,034 (34,034 ) - 8,017 (8,017 ) - intangible assets Research and 86,677 (3,997 ) 82,680 85,294 (15,816 ) 69,478 development Selling, general 187,266 (15,990 ) 171,276 132,786 (11,265 ) 121,521 and administrative Intangible asset 41,600 (41,600 ) - - - - impairment charge Change in acquisition-related (31,398 ) 31,398 - - - - contingent consideration Total costs and 412,097 (64,223 ) 347,874 293,981 (35,098 ) 258,883 expenses Income from 125,174 64,223 189,397 91,325 35,098 126,423 operations Loss on extinguishment of (14,369 ) 14,369 - - - - debt Interest expense (39,591 ) 25,262 (14,329 ) (23,932 ) 14,334 (9,598 ) Interest and other 10,409 (9,325 ) 1,084 2,082 - 2,082 income Income before 81,623 94,529 176,152 69,475 49,432 118,907 income tax Income tax expense 35,000 (13,333 ) 21,667 15,671 - 15,671 Net Income, as $ 46,623 $ 107,862 $ 154,485 $ 53,804 $ 49,432 $ 103,236 adjusted Income per share, $ 0.79 $ 1.84 $ 2.63 $ 0.92 $ 0.84 $ 1.76 basic Income per share, $ 0.73 $ 1.69 $ 2.43 $ 0.89 $ 0.76 $ 1.64 diluted Shares used in computing net income 58,671 58,671 58,671 58,573 58,573 58,573 per share, basic Shares used in computing net income 63,689 63,689 63,689 65,405 65,405 65,405 per share, diluted Salix Pharmaceuticals, Ltd. Condensed Consolidated Balance Sheets (In thousands) September 30, December 31, 2012 2011 (unaudited) (audited) Assets Cash and cash equivalents $ 775,903 $ 292,814 Accounts receivable, net 213,766 151,207 Inventory, net 71,654 49,205 Other assets 759,578 819,743 Total Assets $ 1,820,901 $ 1,312,969 Liabilities and Stockholders' Equity Accounts payable and other $ 1,288,306 $ 763,332 liabilities Total liabilities 1,288,306 763,332 Common stock 59 59 Additional paid-in-capital 621,474 685,315 Other comprehensive loss 65 (111 ) Accumulated deficit (89,003 ) (135,626 ) Total stockholders' equity 532,595 549,637 Total Liabilities and $ 1,820,901 $ 1,312,969 Stockholders' Equity Contact: Salix Pharmaceuticals, Ltd. Adam C. Derbyshire Executive Vice President and Chief Financial Officer or G. Michael Freeman Associate Vice President, Investor Relations and Corporate Communications 919-862-1000
Salix Pharmaceuticals Reports 3Q2012 Results
Press spacebar to pause and continue. Press esc to stop.